Legumain（LGMN）在乳腺、前列腺和肝肿瘤细胞以及组成肿瘤微环境的巨噬细胞中均已被证实过度表达。这支持了LGMN是调控肿瘤发展、侵袭和扩散的至关重要的蛋白质的想法。通过siRNA或化学疗法药物和肽靶向LGMN可以抑制培养中的癌细胞增殖并减少体内肿瘤生长。此外，由于正常细胞与肿瘤或肿瘤相关巨噬细胞（TAMs）相比，LGMN表达显着降低，因此可以将其用作癌症检测和靶向的标记。肿瘤形成受到蛋白质异常表达和细胞结构改变的影响，但肿瘤微环境是关键的决定因素。Legumain（LGMN）是一种体内活性的半胱氨酸蛋白酶，催化了许多蛋白质的降解。它的精确生物学机制包括对肿瘤相关巨噬细胞和肿瘤微环境中的新生血管内皮的影响。本文旨在通过回顾LGMN在肿瘤发生和进展中的功能以及与肿瘤环境的关系来建立彻底研究LGMN在肿瘤微环境中的功能并发现新的肿瘤早期诊断标志物和治疗靶点的基础。版权所有 ©2023 Khan、Khan、Khan、Ud Din、Khan、Khan和Liu。

Legumain (LGMN) has been demonstrated to be overexpressed not just in breast, prostatic, and liver tumor cells, but also in the macrophages that compose the tumor microenvironment. This supports the idea that LGMN is a pivotal protein in regulating tumor development, invasion, and dissemination. Targeting LGMN with siRNA or chemotherapeutic medicines and peptides can suppress cancer cell proliferation in culture and reduce tumor growth in vivo. Furthermore, legumain can be used as a marker for cancer detection and targeting due to its expression being significantly lower in normal cells compared to tumors or tumor-associated macrophages (TAMs). Tumor formation is influenced by aberrant expression of proteins and alterations in cellular architecture, but the tumor microenvironment is a crucial deciding factor. Legumain (LGMN) is an in vivo-active cysteine protease that catalyzes the degradation of numerous proteins. Its precise biological mechanism encompasses a number of routes, including effects on tumor-associated macrophage and neovascular endothelium in the tumor microenvironment. The purpose of this work is to establish a rationale for thoroughly investigating the function of LGMN in the tumor microenvironment and discovering novel tumor early diagnosis markers and therapeutic targets by reviewing the function of LGMN in tumor genesis and progression and its relationship with tumor milieu.Copyright © 2023 Khan, Khan, Khan, Ud Din, Khan, Khan and Liu.